Cogent Biosciences (COGT) Payables (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Payables data on file, last reported at $13.7 million in Q1 2026.

• On a quarterly basis, Payables fell 2.9% year-over-year to $13.7 million in Q1 2026; TTM through Mar 2026 was $13.7 million, a 2.9% decrease from a year earlier, with the FY2025 full-year figure at $9.5 million, down 20.89% from the prior year.
• Payables for Q1 2026 stood at $13.7 million, up from $9.5 million in the prior quarter.
• Over the last five years, Payables for COGT reached as high as $16.6 million in Q2 2025 and fell as low as $3.5 million in Q2 2022.
• Historically, Payables has averaged $10.1 million across 5 years, with a median of $9.9 million in 2023.
• Across the five-year window, Payables soared 1174.6% in 2022 and declined 20.89% in 2025, its largest moves.
• Year by year, Payables stood at $5.8 million in 2022, then surged by 82.39% to $10.7 million in 2023, then climbed by 12.75% to $12.0 million in 2024, then retreated by 20.89% to $9.5 million in 2025, then surged by 44.61% to $13.7 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $13.7 million in Q1 2026, $9.5 million in Q4 2025, and $16.0 million in Q3 2025.